The Third Survey of Prescription Pattern of Psychotropic Drugs in China

Prescription Clinical Trial

Official title:

The Third Survey on China Psychotropic Prescription for Schizophrenia, Depression and Bipolar Disorder

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01668810
• Other study ID #: RISSCH4255
• Status: Recruiting
• Phase: N/A
• First received: August 16, 2012
• Last updated: August 17, 2012
• Start date: July 2012
• Est. completion date: July 2013

Study information

• Verified date: July 2012
• Source: Peking University
• Contact: Yun-Ai Su, Phd.
• Phone: 8610-82801960
• Email: suyunai[@]gmail.com
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

The investigators aimed to examine the psychotropic prescription pattern in China.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 7000
• Est. completion date: July 2013
• Est. primary completion date: September 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria: aged 18-65, inpatient or outpatient, Patient must be willing and able to give written informed consent,the patient suffers from schizophrenia or depression or bipolar disorder -

Exclusion Criteria:aged<18or aged>65

Study Design

Observational Model: Ecologic or Community, Time Perspective: Prospective

Related Conditions & MeSH terms

• Prescription

Locations

Country	Name	City	State
China	Institute of mental health, Peking University	Beijing	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
Peking University	Xian-Janssen Pharmaceutical Ltd.

Country where clinical trial is conducted

China,